Strategic partnerships Leverage Pluristyx and panCELLa’s recent collaborations and integrations (Made Scientific, CellVoyant, Qkine, Solesis) to position as a one-stop solution for iPSC development, gene editing, and scalable manufacturing, offering a streamlined, end-to-end pathway for clients from research to clinical-grade production.

AI-enabled offerings Highlight the new generation of AI-characterised iPSC products and predictive analytics capabilities through the CellVoyant partnership to attract customers seeking accelerated lead times, improved decision-making, and higher success probabilities in cell therapy programs.

Clinical-grade focus Emphasize the merged entity’s aim to become a global leader in clinical-grade, genetically modified off-the-shelf iPSCs with the lowest barriers to entry, targeting biotechs and pharma enterprises seeking ready-to-clinic iPSC solutions and faster commercialization routes.

Manufacturing access Promote integrated GMP-ready workflows and manufacturing partnerships (Made Scientific, Solesis) to reduce handoff risk and timeline drag, appealing to teams needing reliable, scalable production and consistent quality across stages.

Product breadth Position Pluristyx’s end-to-end iPSC product and services portfolio combined with panCELLa’s gene-editing strengths as a differentiator for clients requiring differentiated cell products, gene-modified iPSCs, and differentiated lineages with strong regulatory and development support.